Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Therapy Perspectives
Published in: Drugs & Therapy Perspectives 6/2023

20-05-2023 | Oxybutynin | Practical Issues and Updates

Treat hyperhidrosis with topical therapies first, then dermatological or systemic therapies

Authors: Caroline Fenton, Connie Kang

Published in: Drugs & Therapy Perspectives | Issue 6/2023

Login to get access

Abstract

Hyperhidrosis (HH) includes chronic focal primary HH (PHH) stemming from sweat gland overactivity, and generalised secondary HH (SHH), which warrants investigation for an underlying cause. PHH, which may be axillary, plantar, palmar and/or craniofacial, decreases patients’ quality of life and often goes undiagnosed. Topical therapies, starting with aluminium chloride, are often effective. Additional recommendations for severe or recalcitrant PHH, and in craniofacial HH, are iontophoresis, topical or systemic anticholinergic agents and onabotulinum toxin injections.
Literature
1.
Henning MAS, Bouazzi D, Jemec GBE. Treatment of hyperhidrosis: an update. Am J Clin Dermatol. 2022;23(5):635–46.CrossRefPubMed
2.
McConaghy JR, Fosselman D. Hyperhidrosis: management options. Am Fam Physician. 2018;97(11):729–34.PubMed
3.
Kisielnicka A, Szczerkowska-Dobosz A, Purzycka-Bohdan D, et al. Hyperhidrosis: disease aetiology, classification and management in the light of modern treatment modalities. Postepy Dermatol Alergol. 2022;39(2):251–7.CrossRefPubMedPubMedCentral
4.
Solish N, Bertucci V, Dansereau A, et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg. 2007;33(8):908–23.PubMed
5.
6.
Wilke K, Martin A, Terstegen L, et al. Neurobiology of skin appendages: eccrine, apocrine, and apoeccrine sweat glands. In: Granstein RD, Luger TA, editors., et al., Neuroimmunology of the skin. Berlin: Springer; 2009.
7.
Hornberger J, Grimes K, Naumann M, et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol. 2004;51(2):274–86.CrossRefPubMed
8.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–6.CrossRefPubMed
9.
Thianboonsong T, Kanokrungsee S, Paichitrojjana A, et al. Efficacy and tolerability of 20% aluminum sesquichlorohydrate vs 20% aluminum chloride for the treatment of axillary hyperhidrosis: a randomized controlled trial. Dermatol Ther. 2020;33(6):e14354.CrossRefPubMed
10.
Streker M, Reuther T, Hagen L, et al. Hyperhidrosis plantaris—a randomized, half-side trial for efficacy and safety of an antiperspirant containing different concentrations of aluminium chloride. J Dtsch Dermatol Ges. 2012;10(2):115–9.PubMed
11.
Masur C, Soeberdt M, Kilic A, et al. Safety and efficacy of topical formulations containing 0·5, 1 and 2% glycopyrronium bromide in patients with primary axillary hyperhidrosis: a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2020;182(1):229–31.PubMed
12.
Abels C, Soeberdt M, Kilic A, et al. A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial. Br J Dermatol. 2021;185(2):315–22.CrossRefPubMedPubMedCentral
13.
Yokozeki H, Fujimoto T, Wanatabe S, et al. Topical glycopyrronium tosylate in Japanese patients with primary axillary hyperhidrosis: a randomized, double-blind, vehicle-controlled study. J Dermatol. 2022;49(1):86–94.CrossRefPubMed
14.
Glaser DA, Hebert AA, Nast A, et al. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2019;80(1):128-38.e2.CrossRefPubMed
15.
Pariser DM, Hebert AA, Drew J, et al. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: patient-reported outcomes from the ATMOS-1 and ATMOS-2 phase III randomized controlled trials. Am J Clin Dermatol. 2019;20(1):135–45.CrossRefPubMed
16.
Kirsch B, Smith S, Cohen J, et al. Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: a phase II, randomized, controlled, double-blinded trial. J Am Acad Dermatol. 2020;82(6):1321–7.CrossRefPubMed
17.
Yokozeki H, Fujimoto T, Abe Y, et al. A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis. J Dermatol. 2021;48(3):279–88.CrossRefPubMedPubMedCentral
18.
Artzi O, Loizides C, Zur E, et al. Topical oxybutynin 10% gel for the treatment of primary focal hyperhidrosis: a randomized double-blind placebo-controlled split area study. Acta Derm Venereol. 2017;97(9):1120–4.CrossRefPubMed
19.
Lueangarun S, Sermsilp C, Tempark T. Topical botulinum toxin type A liposomal cream for primary axillary hyperhidrosis: a double-blind, randomized, split-site, vehicle-controlled study. Dermatol Surg. 2018;44(6):e14354.
20.
Wade R, Llewellyn A, Jones-Diette J, et al. Interventional management of hyperhidrosis in secondary care: a systematic review. Br J Dermatol. 2018;179(3):599–608.CrossRefPubMed
21.
Obed D, Salim M, Bingoel AS, et al. Botulinum toxin versus placebo: a meta-analysis of treatment and quality-of-life outcomes for hyperhidrosis. Aesthetic Plast Surg. 2021;45(4):1783–91.CrossRefPubMedPubMedCentral
22.
23.
24.
25.
26.
Wolosker N, Campos JRM, Kauffman P, et al. A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis. J Vasc Surg. 2012;55(6):1696–700.CrossRefPubMed
27.
Schollhammer M, Brenaut E, Menard-Andivot N, et al. Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial. Br J Dermatol. 2015;173(5):1163–8.CrossRefPubMed
28.
29.
Müller C, Berensmeier A, Hamm H, et al. Efficacy and safety of methantheline bromide (Vagantin(®) ) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo-controlled trial. J Eur Acad Dermatol Venereol. 2013;27(10):1278–84.PubMed
Metadata
Title
Treat hyperhidrosis with topical therapies first, then dermatological or systemic therapies
Authors
Caroline Fenton
Connie Kang
Publication date
20-05-2023
Publisher
Springer International Publishing
Published in
Drugs & Therapy Perspectives / Issue 6/2023
Print ISSN: 1172-0360
Electronic ISSN: 1179-1977
DOI
https://doi.org/10.1007/s40267-023-00996-0

Other articles of this Issue 6/2023

Drugs & Therapy Perspectives 6/2023 Go to the issue

Drug Reactions and Interactions

Risk of falls and fractures does not necessarily preclude the use of antihypertensive medications

Correction

Correction to: Mitotane in adrenocortical carcinoma: a profile of its use

Therapy in Practice

Therapy for HIV-associated cryptococcal meningitis: a case report demonstrating a new treatment approach emphasizing updated treatment guidelines

Practical Issues and Updates

Manage mammalian meat allergy by avoiding both the allergen and further sensitization

Disease Management

Common skin conditions in inflammatory bowel disease are manageable

Practical Issues and Updates

Calcitonin gene-related peptide-targeted therapies are effective options for the prevention and treatment of migraine